Last reviewed · How we verify
NCT04788472
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL
Phase 2 trial testing CAR-T cells targeting CD19 and CD22 in B-Cell Acute Lymphoblastic Leukemia, Adult in 28 participants. Completed in 31 August 2024.
31 August 2024
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 28 |
| Start date | 5 March 2021 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CAR-T cells targeting CD19 and CD22 — full drug profile →
Conditions studied
- B-Cell Acute Lymphoblastic Leukemia, Adult — all drugs for B-Cell Acute Lymphoblastic Leukemia, Adult →
Sponsor
Zhejiang University
Who can join
18 and older, any sex, with B-Cell Acute Lymphoblastic Leukemia, Adult. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Trial for the Efficacy and Safety of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Positive B-cell Acute Lymphoblastic Leukemia
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting CD22 for the Treatment of B-Cell Malignancies.
Shah NN, Sokol L. · · 2021 · cited 42× · PMID 34262884 · DOI 10.2147/itt.s288546 -
Next-generation chimeric antigen receptors for T- and natural killer-cell therapies against cancer.
Li Y, Rezvani K, Rafei H. · · 2023 · cited 29× · PMID 37548050 · DOI 10.1111/imr.13255 -
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Adults.
Saleh K, Fernandez A, Pasquier F. · · 2022 · cited 24× · PMID 35406576 · DOI 10.3390/cancers14071805 -
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.
Zhang M, Fu S, Feng J, Hong R, et al · · 2025 · cited 17× · PMID 40244598 · DOI 10.1001/jamaoncol.2025.0674 -
CAR T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Saleh K, Pasquier F, Bigenwald C, De Botton S, et al · · 2023 · cited 11× · PMID 37959347 · DOI 10.3390/jcm12216883 -
Multi-targeted immunotherapeutics to treat B cell malignancies.
Gambles MT, Yang J, Kopeček J. · · 2023 · cited 8× · PMID 37121515 · DOI 10.1016/j.jconrel.2023.04.048 -
Clinical trials for chimeric antigen receptor T-cell therapy: lessons learned and future directions.
Schroeder BA, Jess J, Sankaran H, Shah NN. · · 2022 · cited 8× · PMID 35787551 · DOI 10.1097/moh.0000000000000723
Verify or expand the search:
- PubMed search for NCT04788472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CAR-T cells targeting CD19 and CD22
Trials testing the same drug.
- NCT04740203 — Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL · Phase 1, PHASE2 · unknown
Other recruiting trials for B-Cell Acute Lymphoblastic Leukemia, Adult
Currently open trials in the same condition.
- NCT07199855 — Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymph · Phase 2 · active not recruiting
- NCT06696833 — Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT04214886 — CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies · Phase 1 · active not recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04788472 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04788472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing